Navigation Links
Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo

Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.

This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response compared to placebo (CZP 200mg Q2W: 36.2%, CZP 400mg Q4W: 32.6%, PBO: 11% for ACR50, CZP 200mg Q2W: 24.6%, CZP 400mg Q4W: 12.6%, PBO: 2.9% for ACR70). HAQ-DI** scores were also higher in the combined CZP groups at week 24. In addition patients treated with both doses of CZP also showed greater improvements in PASI 75*** than placebo (62.2% and 60.5% respectively vs 15.1%).

"We know that certolizumab is effective in rheumatoid arthritis but this is the first study to review its efficacy and safety in psoriatic arthritis," commented Dr. Mease, University of Washington, USA and lead author of the study. "Not only were the signs and symptoms of arthritis improved, but so too were patients' physical function and skin manifestations, which is a great breakthrough for us and our patients."

The study followed 409 patients with active psoriatic arthritis who had failed one or more disease modifying anti-rheumatic drugs (DMARDs) including a maximum of one anti-TNF. Patients were randomised 1:1:1 to placebo, or started on a loading dose of 400mg CZP every two weeks for the first four weeks then continued either on 200mg CZP Q2W or 400mg CZP Q4W. Patients receiving placebo who failed to achieve a ≥10% improvement in tender joint count (TJC) and swollen joint count (SJC) at both weeks 14 and 16 were rescued and randomized to one of the CZP arms following loading dose.

CZP use in psoriatic arthritis was associated with a similar safety profile to what has been observed in rheumatoid arthritis. Adverse events occurred at the rates of 68% for the placebo group versus 62% for the combined CZP group, and serious adverse events at 4% for the placebo group versus 7% for the combined CZP group. Two deaths occurred during this 24 wk double-blind phase of the study, one sudden death of unknown cause (CZP 400mg Q4W) and one myocardial infarction (CZP 200mg Q2W).

Abstract Number: LB0001


Contact: Candice Debleu
European League Against Rheumatism

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Young patients with chronic illnesses find relief in acupuncture
3. For Some Breast Cancer Patients, Shorter Radiation Works Well
4. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
5. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
6. Behavioral therapy improves sleep and lives of patients with pain
7. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
8. MSU researcher linking breast cancer patients with alternative therapies
9. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
10. Fishy Smell May Keep Patients From Diabetes Drug
11. AGA offers new recommendations for CRC surveillance for certain patients with IBD
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: